Search: WFRF:(Goh Chee Leok)
> Engfeldt Malin >
Multicenter patch t...
Multicenter patch testing with methylchloroisothizoline/methylisothiazolinone in 100 and 200 ppm within the international contact dermatitis research group
-
- Engfeldt, Malin (author)
- Lund University,Lunds universitet,Yrkes- och miljödermatologi,Forskargrupper vid Lunds universitet,Occupational and Environmental Dermatology,Lund University Research Groups,Skåne University Hospital
-
Ale, Iris (author)
-
- Andersen, Klaus E. (author)
- Odense University Hospital
-
show more...
-
- Elsner, Peter (author)
- Universitätsklinikum Jena
-
- Goh, Chee Leok (author)
- National Skin Centre
-
- Goossens, An (author)
- University Hospitals Leuven
-
- Jerajani, Hemangi (author)
- MGM Medical College
-
- Matsunaga, Kayoko (author)
- Fujita Health University
-
- Bruze, Magnus (author)
- Lund University,Lunds universitet,Yrkes- och miljödermatologi,Forskargrupper vid Lunds universitet,Occupational and Environmental Dermatology,Lund University Research Groups,Skåne University Hospital
-
show less...
-
(creator_code:org_t)
- 2017
- 2017
- English 4 s.
-
In: Dermatitis. - 1710-3568. ; 28:3, s. 215-218
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: The preservative methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) is a well-known contact sensitizer. Historically, there have been different opinions on the optimal patch test concentration of MCI/MI, and both 0.01% and 0.02% aqueous (aq.) have been proposed. In 2011, based on literature reviews, it was recommended that the concentration of 0.02% aq. should be used in the international baseline series. Objectives: The aim of this study was to verify the recommendation from 2011 by comparing the patch test results from consecutive patch testing with MCI/MI 0.01% and 0.02% in clinics representing countries around the world. Patients and Methods: Two thousand seven hundred three consecutive patients with dermatitis in 8 dermatology clinics representing 8 countries were patch tested with MCI/MI 0.01% aq. and, in parallel with MCI/MI 0.02% aq., provisionally included in the baseline series. Results: Contact allergy to MCI/MI at 0.01% and 0.02% was found in 3.7% and 5.6% of the patients, respectively (P G 0.001). Conclusions: Methylchloroisothiazolinone/MI 0.02% aq. (dose, 6 Kg/cm2) diagnoses significantly more contact allergy than 0.01% (dose, 3 Kg/cm2), without resulting in more adverse reactions.Methylchloroisothiazolinone/MI at 0.02% aq. should therefore be continuously used in the international baseline series.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
-
Dermatitis
(Search for host publication in LIBRIS)
To the university's database